title: Clinical effectiveness of Novolin® 30R versus Lantus® combined with Glucobay® treatment in elderly patients with type 2 diabetes mellitus controlled by oral hypoglycaemic agents: A randomized study.
abstract: OBJECTIVE
  To compare the treatment effects of Novolin® 30R(a), versus Lantus(®a) combined with acarbose (Glucobay®), in elderly patients with type 2 diabetes mellitus.
  
  
  METHODS
  Patients (aged > 60 years) with type 2 diabetes mellitus were randomized to receive either Novolin® 30R(a) (initial dose 0.5 IU/kg) or Lantus(®a) (initial dose 0.2 IU/kg) combined with 50 mg acarbose. After a 32-week treatment period, the following parameters were measured: blood glucose control; blood lipid levels; body mass index; proportion of patients achieving a glycosylated haemoglobin (HbA1c) level <7.5%; rate of hypoglycaemic events; change in fasting blood glucose levels from baseline in patients stratified according to their baseline HbA1c level.
  
  
  RESULTS
  A total of 188 patients were enrolled in the study. After 32 weeks' treatment, compared with baseline levels, there were significant reductions in FBG, 2 h-postprandial blood glucose during an oral glucose tolerance test, HbA1c, total cholesterol, triglycerides and low-density lipoprotein cholesterol values in both groups. Although there were fewer hypoglycaemic events in the Lantus® combined with Glucobay® group compared with the Novolin® 30R group, the difference was not significant.
  
  
  CONCLUSIONS
  Novolin® 30R and Lantus® combined with acarbose both had beneficial effects on blood glucose control and blood lipid levels in elderly patients with type 2 diabetes mellitus.
authors.affiliation: Department of Geriatric Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China.
authors.forename: Yixuan
authors.initials: Y
authors.lastname: Sun
authors.affiliation: Department of Geriatric Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China.
authors.forename: Li
authors.initials: L
authors.lastname: Shao
authors.affiliation: Department of Geriatric Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China.
authors.forename: Xianping
authors.initials: X
authors.lastname: Niu
authors.affiliation: Department of Geriatric Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Geriatric Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China.
authors.forename: Jianli
authors.initials: J
authors.lastname: Ge
authors.affiliation: Department of Geriatric Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China.
authors.forename: Hua
authors.initials: H
authors.lastname: Jiang
authors.affiliation: Department of Geriatric Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China dongfangzhanghua@126.com.
authors.forename: Hua
authors.initials: H
authors.lastname: Zhang
mesh_terms: D020909:Acarbose / Q000627:therapeutic use*; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D000069036:Insulin Glargine / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D011446:Prospective Studies
chemical_list: D020909:Acarbose; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000069036:Insulin Glargine; D008055:Lipids; C517652:hemoglobin A1c protein, human
keywords: Glucobay®; Lantus®; Novolin® 30R; Type 2 diabetes mellitus; elderly patients